Greetings
Welcome to the pilot issue of 340B Report. We’re so glad to have you aboard! And now, let’s get to the news.
BREAKING: Drugmaker Xspire Owes 340B Refunds
Xspire Pharma, a privately held, specialty pharmaceutical company, owes refunds for overcharges to 340B covered entities for covered outpatient drugs sold from Nov. 1, 2012 to Aug. 1, 2019, according to a public notice the company posted either late late Jan. 6 or early Jan. 7 on the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) website.
Greetings Welcome to the pilot issue of 340B Report. We’re so glad to have you aboard! And now, let’s get to the news. BREAKING: Drugmaker Xspire Owes 340B Refunds Xspire Pharma, a privately held, specialty pharmaceutical company, owes refunds for […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
